• Lauren S Ranard, Justin A Fried, Marwah Abdalla, D Edmund Anstey, Raymond C Givens, Deepa Kumaraiah, Susheel K Kodali, Koji Takeda, Dimitrios Karmpaliotis, LeRoy E Rabbani, Gabriel Sayer, Ajay J Kirtane, Martin B Leon, Allan Schwartz, Nir Uriel, and Amirali Masoumi.
• Division of Cardiology, Department of Medicine (L.S.R., J.A.F., M.A., D.E.A., R.C.G., D. Kumaraiah, S.K.K., D. Karmpaliotis, L.E.R., G.S., A.J.K., M.B.L., A.S., N.U., A.M.), Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY.
• Circ Heart Fail. 2020 Jul 1; 13 (7): e007220.

AbstractThe novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic. It has spread to >187 countries with a rapidly growing number of affected patients. Underlying cardiovascular disease is associated with more severe manifestations of COVID-19 and higher rates of mortality. COVID-19 can have both primary (arrhythmias, myocardial infarction, and myocarditis) and secondary (myocardial injury/biomarker elevation and heart failure) cardiac involvement. In severe cases, profound circulatory failure can result. This review discusses the presentation and management of patients with severe cardiac complications of COVID-19 disease, with an emphasis on a Heart-Lung team approach in patient management. Furthermore, it focuses on the use of and indications for acute mechanical circulatory support in cardiogenic and/or mixed shock.

58 keywords...

hide…